Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02886000
Other study ID # NCI-2014-01080
Secondary ID NCI-2014-01080HH
Status Recruiting
Phase Phase 2
First received August 23, 2016
Last updated September 6, 2016
Start date June 2014

Study information

Verified date August 2016
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.


Description:

PRIMARY OBJECTIVES:

I. To compare the immunogenicity at week 12 of a MUC1 peptide vaccine with adjuvant (MUC1 peptide-poly-ICLC adjuvant vaccine) (administered at 0, 2, and 10 weeks) in participants with a history of an advanced adenoma, randomized to receive MUC1 peptide vaccine versus placebo.

SECONDARY OBJECTIVES:

I. To evaluate the ability of the vaccine to elicit a long‐term memory response.

II. To compare the adenoma recurrence rate from surveillance exams occurring at least 1 year and up to 3 years after week 0 vaccine administration - MUC1 versus placebo.

III. To compare the adenoma recurrence rates between MUC1 and placebo by excluding the following types of adenomas: participants with adenomas =< 5 mm; participants with adenomatous tissue which may represent residual adenoma at the site of the previous advanced adenoma; participants with adenomatous tissue detected in the same segment of the bowel as the previous advanced adenoma.

IV. To assess adverse events to the MUC1 peptide vaccine in comparison to placebo during Parts I and II.

V. To assess patient reported injection site reaction events from the Vaccine Report Card.

TERTIARY OBJECTIVES:

I. To compare the anti‐MUC1 antibody titer at the time of surveillance colonoscopy for the purpose of evaluating the anti‐MUC1 antibody response in relation to adenoma recurrence.

II. To evaluate MUC1 expression on baseline advanced adenomas and on recurrent adenomas detected at surveillance colonoscopy.

III. To evaluate levels of circulating myeloid derived suppressor cells (MDSC) in the vaccinated and the placebo group and correlate with anti‐MUC1 antibody levels and adenoma recurrence.

IV. To establish a biospecimen repository archive including live cells, plasma, and germline deoxyribonucleic acid (DNA) for future immunologic (e.g. MUC1‐specific T cells) and other assays (systems biology approach to detect differences between responders and non‐responders), testing not currently accommodated within the budget of this trial.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine subcutaneously (SC) in weeks 0, 2 and 10 and a booster injection in week 53.

ARM II: Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.

After completion of treatment, patients are followed up every 6 months for up to 3 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender Both
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

- History of at least one of the following conditions in the previous 12 months:

- Colorectal adenoma(s) >= 1 cm in maximal diameter

- Colorectal adenoma(s) with villous or tubulovillous histology

- Colorectal adenoma(s) with high grade (severe) dysplasia

- Presumptive evidence that all adenomatous lesions, including qualifying advanced adenoma, have been completely removed

- Ability to understand and the willingness to sign a written informed consent document

- Willingness to undergo screening tests and procedures

- Willingness to provide blood samples for toxicity monitoring and research purposes

- Not pregnant or nursing; note: a negative (serum or urine) pregnancy test must be documented =< 7 days prior to registration/randomization for women of childbearing potential

- Willingness to employ adequate contraception through week 53 of the study; note: women of childbearing potential and men must agree to use adequate contraception (hormonal, barrier method of birth control, abstinence) prior to study entry and for the period of active vaccination (through week 53); should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her physician immediately

- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

- Hemoglobin greater than 90% of the lower limit of institutional normal

- Platelets >= 100 B/L (10^9/L)

- White blood cell (WBC) > 2.5 B/L (10^9/L)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional upper limit of normal

- Alkaline phosphatase =< 1.5 x institutional upper limit of normal

- Total bilirubin =< 1.5 x institutional upper limit of normal

- Blood urea nitrogen (BUN) =< 1.5 x institutional upper limit of normal

- Creatinine =< 1.5 x institutional upper limit of normal

- Antinuclear antibody (ANA) test result excludes overt autoimmune disease; note: test result may be reported in any of the following formats: =< 1:160, negative, or < 1.0

Exclusion Criteria:

- History of any colorectal cancer

- History of other malignancy =< 5 years prior to the registration/randomization evaluation, with the exception of basal cell or squamous cell skin cancer

- Presence of an active acute or chronic infection or uncontrolled illness including, but not limited to unstable congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Acquired immunosuppressive diseases such as active human immunodeficiency virus (HIV) infection or congenital diseases of immunity

- History of heritable cancer syndrome (familial adenomatous polyposis [FAP], hereditary nonpolyposis colorectal cancer [HNPCC])

- History of auto-immune disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, Hashimoto's thyroiditis, or Grave's disease

- Current or planned use of immunomodulators including: infliximab, 6-MP (mercaptopurine), methotrexate, cyclosporine, or other immunomodulatory drugs

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent

- Pregnant women

- Breastfeeding women

- Diagnosis of nonalcoholic steatohepatitis (NASH) and a NAFLD (nonalcoholic fatty liver disease) activity score (NAS) >= 5; NOTES and EXCEPTIONS: NAS is based on findings from a liver biopsy; participants with NAS of =< 2 are eligible for enrollment; participants with NAS of 3-4 must be discussed with the principal investigator and Division of Cancer Prevention (DCP) before enrollment to consider other risk factors (i.e., obesity, alcohol intake); participants with a prior diagnosis of NASH and no available NAS must be discussed with the principal investigator and DCP before enrollment to considered risk factors (i.e., obesity, alcohol intake)

- Receiving any other investigational agent =< 3 months prior to registration/randomization, except innocuous agents with no known interaction with the study agent (e.g., standard dose multivitamins or topical agents for limited skin conditions)

- Any use of oral corticosteroids =< 12 weeks prior to registration/randomization

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies
Biological:
MUC1 Peptide-Poly-ICLC Vaccine
Given SC
Other:
Quality-of-Life Assessment
Ancillary studies
Saline
Given SC

Locations

Country Name City State
Puerto Rico University of Puerto Rico San Juan
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States Kansas City Veterans Affairs Medical Center Kansas City Missouri
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania
United States University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Other Anti-MUC1 antibody titer by ELISA Comparisons between MUC1 and placebo will be performed using a two-sample t-test or Wilcoxon rank sum test, as appropriate. All categorical variables will be analyzed using chi-square tests or Fisher's exact test. At approximately week 156 No
Other Change in levels of circulating MDSC in peripheral blood mononuclear cells by flow cytometry MDSC levels will be correlated with anti-MUC1 antibody levels and adenoma recurrence. Descriptive statistics and simple scatter plots will be generated to review the continuous biomarker data. In addition, for continuous biomarker values, the actual and percent change in the level of each of the biomarkers from baseline to post-baseline time points will be explored within each arm using Wilcoxon signed rank tests, and paired sample t-tests. Baseline to up to 3 years No
Other Change in MUC1 expression Descriptive statistics and simple scatter plots will be generated to review the continuous biomarker data. In addition, for continuous biomarker values, the actual and percent change in the level of each of the biomarkers from baseline to post-baseline time points will be explored within each arm using Wilcoxon signed rank tests, and paired sample t-tests. Baseline to up to 3 years No
Other Establishment of a biospecimen repository archive including live cells, plasma, and germline DNA for future immunologic and other assays Up to 3 years No
Primary Change in anti-MUC1 immunoglobulin G (IgG) levels as determined by enzyme-linked immunosorbent assay (ELISA) The ratio of the week 12 to week 0 IgG levels will be calculated and compared between the MUC1 vaccine and placebo. The Wilcoxon Rank-Sum test will be used. For all measurements of response (i.e. the primary endpoint), the 95% confidence intervals will also be provided. Week 0 to week 12 No
Secondary Adenoma recurrence rate assessed using surveillance exams Up to 3 years No
Secondary Booster response At week 55 No
Secondary Booster response At week 52 No
Secondary Incidence of adverse events as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 The maximum grade for each type of adverse event will be recorded for each participant and frequency tables will be reviewed to determine the overall patterns. The number and severity of adverse events (overall and by arm) will be tabulated and summarized across all grades. Grade 3+ adverse events will be similarly described and summarized separately. Frequency distributions, graphical techniques, and other descriptive measures will form the basis of these analyses. Up to 57 weeks Yes
Secondary Incidence of participant-reported injection site reaction collected using the participant completed Vaccine Report Card Descriptive statistics will be used to summarize these data and compare the data between study arms. Up to 57 weeks No
Secondary Proportion of patients with at least a 2-fold increase in the IgG ratio At 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT04516785 - Reducing Colonoscopies in Patients Without Significant Bowel Disease
Recruiting NCT05381792 - Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia
Withdrawn NCT05606081 - Predicting Risk for Post-polypectomy Colorectal Cancer N/A
Recruiting NCT05576506 - Application of Hyperspectral Imaging Analysis Technology in the Diagnosis of Colorectal Cancer Based on Colonoscopic Biopsy
Active, not recruiting NCT03796884 - Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Phase 2
Completed NCT05508503 - A Study on a Blood-based Dual-target Test for CRC Detection
Recruiting NCT02935049 - Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique N/A
Completed NCT05477836 - Feasibility and Safety of MiWEndo-assisted Colonoscopy N/A
Active, not recruiting NCT05740137 - Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy N/A
Active, not recruiting NCT05754229 - Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy N/A
Completed NCT03234725 - Analysis of New Endoscopic Features and Variable Stiffness in Colonoscopy: Prospective Randomised Trial
Completed NCT05913453 - Technical Failure During Colorectal Endoscopic Full Thickness Resection (EFTR): The "Through Thick and Thin" Study
Recruiting NCT05261932 - Research on Endoscopic Precision Biopsy.
Completed NCT02521727 - To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas
Completed NCT02226185 - Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence Phase 2/Phase 3
Completed NCT00298545 - Effect of Vitamin D and Calcium on Genes in the Colon Phase 1
Completed NCT03268655 - Ginger and Gut Microbiome (GINGER) N/A
Active, not recruiting NCT04952129 - Optimal Selenium for Bowel Polyps (OSCAR) Phase 1
Recruiting NCT04444908 - Development and Validation of an Artificial Intelligence-assisted Strategy Selection System for Colonoscopy Cleaning